 Life Science Investor Mandates
(Feb. 15 - Feb. 21
)
|
|
|
|
|
Invests Up to $10M in Novel Software-Based Healthcare Technologies with Focus in North America
|
|
Invests Broadly in Medtech, Diagnostics, and Digital Health with Strong Strategic Value
|
|
Seeks Early-Stage Investment Opportunities in All Sectors
|
|
Invests in Ontario-Based Life Science Companies with Strongest Interest in Healthcare IT/Digital Health
|
|
LSN's Sourcing & Ranking Service (SRS) provides clients with an opportunity to quickly source, vet, rank and engage with partners that are licensing global technology assets.
|
|
Click to see investors that are a fit for your product and stage of development
|
|
Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you
|
|
Click here if you want to receive free, targeted early stage dealflow for your life science investment firm
|
|
 |
|
The Redefining Early Stage Investments Conference (RESI) is now offering an Investor Spotlight Package, which for the first time allows investor firms to be featured and stand out from more than 300+ investors attending the 2018 RESI Toronto conference.
Investor Spotlight Package includes the following:
- A Dedicated, Branded Partnering Table in the partnering forum. This is your table and a great opportunity to have an established highly visible spot in the partnering room where companies can meet you. The table will be branded by your firm's logo and name.
- Featured Investor Profile on the RESI website, in the hard copy and digital version of the RESI Conference Program Guide, and in the RESI Partnering System - making your investment mandate visible to RESI attendees.
- Special mailings of your firm's profile to all RESI Companies that are a fit for your firm's mandate.
|
 |
|
|
An interview with Anton Neschadim
CEO, ImmunoBiochem
- By Chris Cummings
Senior Marketing Manager, LSN
|
|
Chris Cummings: What is your background, and how long have you been working in the life science space?
Anton Neschadim: I am a scientist-entrepreneur. I have a very deep, multi-disciplinary science background that I ultimately combined with a business degree, all from the University of Toronto. I am a lateral thinker, and as such always strived to be a subject-matter expert across multiple areas. And so, contrary to the traditional path of specialization in academia, I wanted to become a problem solver and innovator, and sought to master additional disciplines with every degree - chemistry, physics, immunology, cancer research, regenerative medicine. I believe that being able to draw on knowledge from multiple disciplines is key to generating creative insights. I transitioned into industry eight years ago, in the final year of my PhD, and took up a drug development role in a biologics program, while continuing to work in an academic lab evenings and weekends to amass more than 25 manuscripts and patents. Three years ago, I have focused on leading ImmunoBiochem with an exciting novel biologics program.
Chris Cummings: Are you currently fundraising? What previous financing or milestones has your company achieved (that you can disclose)?
Anton Neschadim: We are always fundraising, and are targeting to close another round led by current investors and partners in March. Our first deal was with one of the RESI sponsors and helped us develop fully-human antibody molecules for our lead target, and the subsequent angel-led round allowed us to develop a lead that we showed to be both efficacious and safe in preclinical animal tumor models. This new round will take our lead molecule into large animal studies, but we are eager to get into the clinic and are looking for additional capital to get us there...
|
|
 As Next Phase discussed two weeks ago, the world of early stage biotech and medtech investment is far less than straightforward and CEOs often have limited resources for learning where they fit into the capital landscape. In this article, we'll look more closely at how LSN designed the LSN Investor Platform to address this problem.
Finding and Connecting with Investors that are a Fit for Your Company
LSN has found that the biggest difficulty for fundraising executives is identifying active investors that are a fit for their stage of development and product. When raising a seed or series A financing, most executives go straight to a few brand name VCs and angel groups in their backyard...
|
Campaign Component
|
Typical Cost
|
|
Creating and maintaining your branding, messaging, marketing collateral and web presence for a year
|
$25,000 - $30,000
|
|
One conference per quarter, travel and expenses
|
$12,000 - $20,000
|
|
1-2 week road trip per quarter, two people
|
$10,000 - $15,000
|
|
Global target list of investors and campaign infrastructure
|
$10,000 - $12,000
|
|
Legal and professional fees
|
$10,000 - $20,000
|
|
TOTAL
|
$67,000 - $97,000
|
|
|
|
Created & Produced by
|
 |
|
|
|
